Joinn Laboratories(China)Co vs Charles River Laboratories: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Joinn Laboratories(China)Co (603127.CG)

Q3 202614 Jul – 7 Aug 2026

▲3▼1

Joinn profit surge and CRO sector rally drive gains

H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.
This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.
Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.
It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.
CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.
It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.
Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.
It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

July 202614 Jul – 7 Aug 2026

▲3▼1

Joinn profit surge and CRO sector rally drive gains

H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.
This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.
Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.
It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.
CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.
It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.
Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.
It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

Latest14 Jul – 7 Aug 2026

▲3▼1

Joinn profit surge and CRO sector rally drive gains

H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.
This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.
Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.
It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.
CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.
It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.
Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.
It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.

Charles River Laboratories (CRL)

Q3 202618 Jun – 21 Aug 2026

▲4

CRL's biotech recovery and AI deals drive 89% rally

AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.
New collaboration that expands demand and technology positioning, directly driving future revenue.
Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.
Analyst upgrade reflects improving fundamentals and boosts investor sentiment.
Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.
Earnings beat and guidance raise confirm operational turnaround, a key price driver.
DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.
Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

July 202618 Jun – 21 Aug 2026

▲4

CRL's biotech recovery and AI deals drive 89% rally

AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.
New collaboration that expands demand and technology positioning, directly driving future revenue.
Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.
Analyst upgrade reflects improving fundamentals and boosts investor sentiment.
Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.
Earnings beat and guidance raise confirm operational turnaround, a key price driver.
DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.
Summarizes the powerful rally and underlying operational improvements that continue to support the stock.

Latest18 Jun – 21 Aug 2026

▲4

CRL's biotech recovery and AI deals drive 89% rally

AI drug discovery partnership with Lilly TuneLab Charles River will provide nonclinical testing for biotechs using Lilly's AI/ML platform, expanding service demand and integrating its expertise with AI to speed drug development. This new revenue stream supports growth and shows CRL is adapting to industry shifts.
New collaboration that expands demand and technology positioning, directly driving future revenue.
Morgan Stanley upgrade on biopharma funding strength Morgan Stanley upgraded CRL to Overweight and raised its price target to $220, citing increased biopharma funding that benefits its small and mid-sized biotech clients (40-45% of revenue). This signals confidence in CRL's core market recovery.
Analyst upgrade reflects improving fundamentals and boosts investor sentiment.
Q2 earnings beat and raised EPS guidance CRL beat Q2 estimates and raised full-year adjusted EPS guidance to $11.30, with DSA segment showing first organic growth since 2023 and a four-year high book-to-bill. Management cited recovering biopharma demand, especially from small/mid biotech clients.
Earnings beat and guidance raise confirm operational turnaround, a key price driver.
DSA recovery fuels 88.6% yearly stock gain CRL shares have soared 88.6% over the past year, driven by DSA recovery, strong bookings, and buybacks. Net bookings rose 12.6% sequentially to $701 million, backlog hit $1.97 billion, and book-to-bill reached 1.19x, the highest in nearly four years.
Summarizes the powerful rally and underlying operational improvements that continue to support the stock.